| human | Q5 |
| P106 | occupation | researcher | Q1650915 |
| Q34522152 | A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease |
| Q36100445 | A perspective on the selection of unrelated donors and cord blood units for transplantation |
| Q81163082 | A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study |
| Q34272554 | A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation |
| Q93086096 | Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial |
| Q48596388 | Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders |
| Q75382137 | Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience |
| Q33729489 | Allogeneic hematopoietic cell transplant for prolymphocytic leukemia |
| Q36404698 | Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia |
| Q34374133 | Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood |
| Q35847465 | Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia |
| Q96133865 | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades |
| Q37334733 | Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality |
| Q80390085 | Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease |
| Q38400458 | Challenges and potential solutions for recruitment and retention of hematopoietic cell transplantation physicians: the National Marrow Donor Program's System Capacity Initiative Physician Workforce Group report. |
| Q90925290 | Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia |
| Q38388775 | Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial |
| Q100420886 | Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS |
| Q44391209 | Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells |
| Q34284225 | Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies |
| Q40115117 | Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolesce |
| Q33911314 | Cord-Blood Transplantation in Patients with Minimal Residual Disease |
| Q57034840 | Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation |
| Q36754109 | Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia |
| Q45245162 | Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation |
| Q49904514 | Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most |
| Q39674948 | Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis |
| Q37304130 | Donor and recipient sex in allogeneic stem cell transplantation: what really matters |
| Q64906033 | Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders. |
| Q36305355 | Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders |
| Q36002866 | Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning |
| Q77725444 | Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children |
| Q47405646 | Final adult height of patients who received hematopoietic cell transplantation in childhood |
| Q36941123 | Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation |
| Q36763834 | Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation |
| Q34404171 | Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning |
| Q90035608 | HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients |
| Q34768153 | HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation |
| Q90798973 | HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Non-Malignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide |
| Q34107708 | HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category |
| Q44468881 | HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies |
| Q37849257 | Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: an opportunity to revisit the controversy regarding cord blood banking for private use. |
| Q44582235 | Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients |
| Q37596625 | Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation |
| Q35958215 | Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation |
| Q38681322 | Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia |
| Q34198055 | Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia |
| Q34268509 | Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201 |
| Q80694732 | Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders |
| Q89857629 | KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation |
| Q91159374 | KIR Donor Selection: Feasibility in Identifying better Donors |
| Q36067042 | Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation |
| Q35153813 | Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia |
| Q80337240 | Limits of HLA mismatching in unrelated hematopoietic cell transplantation |
| Q37661792 | Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation |
| Q37296965 | Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis |
| Q44189578 | Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc |
| Q33653406 | Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial |
| Q37482272 | Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? |
| Q91244865 | More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling |
| Q58554191 | Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia |
| Q37249970 | National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants |
| Q35143457 | Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia |
| Q34996382 | Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children |
| Q34630152 | Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives |
| Q34353744 | Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation |
| Q59810053 | Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A |
| Q35849011 | Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy |
| Q36023505 | Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission |
| Q95397658 | Outcome of pediatric hematopoietic stem cell transplant recipients requiring mechanical ventilation |
| Q36609579 | Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission |
| Q37276359 | Peripheral-blood stem cells versus bone marrow from unrelated donors |
| Q38773051 | Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation |
| Q46014459 | Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Cons |
| Q91168759 | Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children |
| Q89998053 | Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources |
| Q46447367 | Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation |
| Q41842015 | Prospective monitoring for alloimmunization in cord blood transplantation: "virtual crossmatch" can be used to demonstrate donor-directed antibodies |
| Q54396385 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. |
| Q73627489 | Reduced toxicity and prompt engraftment after minimal conditioning of a patient with Fanconi anemia undergoing hematopoietic stem cell transplantation from an HLA-matched unrelated donor |
| Q37457111 | Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. |
| Q44612726 | Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome |
| Q44215737 | Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases |
| Q46361757 | Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin |
| Q44557805 | Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia |
| Q37169285 | Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection |
| Q36515278 | Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies |
| Q41202536 | Severe combined immunodeficiency (SCID) presenting with neonatal aplastic anemia. |
| Q37425409 | Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment |
| Q34087133 | Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse |
| Q96827787 | Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors |
| Q54291837 | Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. |
| Q34233378 | Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome |
| Q36958013 | Success of allogeneic marrow transplantation for children with severe aplastic anaemia |
| Q44678071 | Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia |
| Q90461947 | The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases |
| Q36463393 | The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy |
| Q36907865 | The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors |
| Q45895933 | The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia |
| Q37041913 | Thyroid function following hematopoietic cell transplantation in children: 30 years' experience |
| Q34640562 | Towards an HIV cure: a global scientific strategy |
| Q37623558 | Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. |
| Q35073850 | Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial |
| Q37117637 | Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience |
Search more.